Palvella Therapeutics (PVLA) Common Equity: 2013-2024
Historic Common Equity for Palvella Therapeutics (PVLA) over the last 11 years, with Sep 2024 value amounting to -$87.4 million.
- Palvella Therapeutics' Common Equity fell 386.48% to -$87.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$87.4 million, marking a year-over-year decrease of 386.48%. This contributed to the annual value of -$74.5 million for FY2023, which is 366.69% down from last year.
- As of Q3 2024, Palvella Therapeutics' Common Equity stood at -$87.4 million, which was down 8.14% from -$80.8 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Common Equity registered a high of $53.9 million during Q3 2021, and its lowest value of -$87.4 million during Q3 2024.
- Its 3-year average for Common Equity is -$6.5 million, with a median of $27.9 million in 2022.
- Per our database at Business Quant, Palvella Therapeutics' Common Equity soared by 139.53% in 2020 and then slumped by 597.30% in 2024.
- Over the past 5 years, Palvella Therapeutics' Common Equity (Quarterly) stood at $31.0 million in 2020, then spiked by 63.58% to $50.8 million in 2021, then tumbled by 44.97% to $27.9 million in 2022, then crashed by 366.69% to -$74.5 million in 2023, then slumped by 386.48% to -$87.4 million in 2024.
- Its Common Equity stands at -$87.4 million for Q3 2024, versus -$80.8 million for Q2 2024 and -$76.9 million for Q1 2024.